Anhedonia – the reduced ability to experience or respond to pleasure – is an important symptom domain for many psychiatric disorders. It is particularly relevant to depression and other mood disorders and it is a diagnostic criterion of a major depressive episode. Developing safe and effective pharmacological interventions for anhedonia is a critical public health need. The current chapter will review the state of the field with respect to both the efficacy of currently available pharma-cotherapies for anhedonia and the recent clinical research focusing on new brain targets, including the kappa-opioid receptor and the KCNQ2/3 receptors. The evidence for anti-anhedonic effects of ketamine and psychedelic agents will be reviewed, as well.
CITATION STYLE
Klein, M. E., Grice, A. B., Sheth, S., Go, M., & Murrough, J. W. (2022). Pharmacological Treatments for Anhedonia. In Current Topics in Behavioral Neurosciences (Vol. 58, pp. 467–490). Springer Science and Business Media Deutschland GmbH. https://doi.org/10.1007/7854_2022_357
Mendeley helps you to discover research relevant for your work.